Skip to main content

Advertisement

Table 3 Summary of Adverse Events (AEs)

From: Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial

Endpoint LMWF-5A KL grade 4 (n = 144) LMWF-5A KL grade 2–4 (n = 1076) Saline KL grade 2–4 (n = 931)
One or more AE 49 (34.0%) 381 (35.4%) 386 (41.5%)
One or more related AE 10 (6.9%) 11 (1.0%) 19 (2.0%)
AE by severitya
mild 25 (17.4%) 264 (24.5%) 253 (27.2%)
moderate 22 (15.3%) 162 (15.1%) 190 (20.4%)
severe 2 (1.4%) 35 (3.3%) 32 (3.4%)
Serious AE (SAE) 0 (0%) 15 (1.4%) 20 (2.1%)
AE leading to withdrawal 0 (0%) 0 (0%) 0 (0%)
AE resulting in death 0 (0%) 0 (0%) 0 (0%)
  1. aSubjects could have AEs in more than one severity category. KL, Kellgren Lawrence